Wockhardt receives FDA OK for generic Augmentin suspension
This article was originally published in Scrip
Morton Grove Pharmaceuticals, the Chicago-based subsidiary of India's Wockhardt, has received US FDAapproval for marketing an oral suspension of a combination containing 250mg/5ml of amoxicillin and 62.5mg/5ml of clavulanate potassium, a generic version of GlaxoSmithKline's anti-infective, Augmentin. Wockhardt said that it was the first company to receive an ANDA approval for this strength of Augmentin.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.